Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of seven new drugs. These drugs include treatments for hypertension, heart failure, reproductive health, and other medical conditions, marking a significant advancement in the company’s product offerings and potentially strengthening its position in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in the creation of various medications, including treatments for hypertension, heart failure, and reproductive health, with a market focus on China.
Average Trading Volume: 12,715,868
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.74B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.